Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00303784
Other study ID # CDR0000455583
Secondary ID MRC-PATCHEU-2051
Status Recruiting
Phase Phase 3
First received
Last updated
Start date March 2006
Est. completion date August 2021

Study information

Verified date November 2020
Source University College, London
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: The increasingly prolonged and extended use of androgen deprivation therapy (ADT) in the treatment of prostate cancer, usually achieved through the administration of LHRH agonists, has raised concerns about long-term toxicities, in particular osteoporosis and adverse metabolic changes which may be associated with type II diabetes and increased cardiovascular risk. An alternative approach is to investigate other methods of ADT. Oral oestrogen has been shown to be as effective as LHRH and surgical orchidectomy in achieving castrate levels of testosterone and has equivalent or improved prostate cancer outcomes but is not used routinely as first-line therapy because of the risk of cardiovascular system (CVS) complications. The CVS complications have been attributed to first-pass hepatic metabolism. Administering oestrogen parenterally avoids the entero-hepatic circulation and so is expected to mitigate the risk of CVS toxicity whilst still effectively suppressing testosterone to castrate levels. This hypothesis has been supported by results from the early stages of this trial which have provided sufficient indication of the safety and efficacy of the patches to warrant further investigation of the treatment in this setting, as recommended by the IDMC.. PURPOSE: This randomized phase III trial is studying how well the estrogen skin patch works compared with luteinizing hormone-releasing hormone agonist injections in treating patients with locally advanced or metastatic prostate cancer.


Description:

OBJECTIVES: Primary - Compare the progression-free survival and overall survival of patients with locally advanced or metastatic prostate cancer treated with transcutaneous estrogen patches vs luteinizing hormone-releasing hormone analogues. Secondary - Compare the cardiovascular system-related morbidity and mortality in patients treated with these regimens - Compare the activity of these treatments, in terms of castrate level of hormones, failure-free survival, and biochemical failure, in these patients. - Compare other toxicities, including osteoporosis, hot flushes, gynecomastia, and anemia, in patients treated with these regimens. - Compare the quality of life of patients treated with these regimens. OUTLINE: This is a randomized, controlled, multicenter study. Patients are randomized to 1 of 2 treatment arms at 1(control):1 (patch) ratio. - Arm I (control): Patients receive luteinizing hormone-releasing hormone agonists as per local practice in the absence of unacceptable toxicity. - Arm II (patch): Patients receive 4 transcutaneous estrogen patches, changing twice weekly for 4 weeks. Patients' testosterone levels are measured at week 4. Patients whose testosterone level is > 1.7 nmol/L continue to receive patch as before and have their testosterone level measured every 2 weeks. Patients whose testosterone level is < 1.7 nmol/L at week 4 or any other point receive 3 transcutaneous estrogen patches changed twice weekly in the absence of unacceptable toxicity. Quality of life is assessed at baseline; at weeks 4, 8, and 12; every 3 months for 24 months. After completion of study treatment, patients are followed periodically. Peer Reviewed and Funded or Endorsed by Cancer Research UK PROJECTED ACCRUAL: A total of 2200 patients will be accrued for this study.


Recruitment information / eligibility

Status Recruiting
Enrollment 2200
Est. completion date August 2021
Est. primary completion date August 2021
Accepts healthy volunteers No
Gender Male
Age group N/A to 120 Years
Eligibility DISEASE CHARACTERISTICS: - Must meet 1 of the following criteria: - Newly diagnosed patients with any of the following: - Stage T3 or T4, NX, M0 histologically confirmed prostate adenocarcinoma with prostate-specific antigen (PSA) = 20 ng/mL or Gleason score = 6 - Any T, N+, M0, or any T, any N, M+ histologically confirmed prostate adenocarcinoma - Multiple sclerotic bone metastases with a PSA = 50 ng/mL without histological confirmation - Patients with histologically confirmed prostate adenocarcinoma previously treated with radical surgery or radiotherapy who are currently in relapse with on of the following: - PSA = 4 ng/mL and rising with doubling time less than 6 months - PSA = 20 ng/mL - Must have written informed consent - Intention to treat with long-term androgen-deprivation therapy - Normal testosterone level prior to hormonal treatment PATIENT CHARACTERISTICS: - WHO performance status 0-2 - No other prior or current malignant disease or cardiovascular system disease that is likely to interfere with study treatment or assessment - No cardiovascular disease, including any of the following: - History of cerebral ischemia (e.g., stroke or transient ischemic attack) within the past 2 years - History of deep vein thrombosis or pulmonary embolism confirmed radiologically - History of myocardial infarction (MI) within the past 6 months OR MI more than 6 months ago with evidence of q-wave anterior infarct on ECG - ECHO or MUGA required for patients with history of ischemic heart disease - Left Ventricular Ejection Fraction = 40% - No condition or situation that could preclude protocol treatment or compliance with follow-up schedule PRIOR CONCURRENT THERAPY: - See Disease Characteristics - At least 12 months since prior adjuvant or neoadjuvant hormonal therapy for localized prostate cancer AND therapy lasted = 12 months in duration - No prior systemic therapy for locally advanced or metastatic prostate cancer - No concurrent participation in another clinical trial of prostate cancer treatment that would preclude study therapy or outcome measures - Concurrent prophylactic radiotherapy to prevent gynecomastia allowed

Study Design


Intervention

Drug:
Goserelin
3.6mg implant, in pre-filled syringe
Estradiol
Each patch contains 3 mg of estradiol hemihydrate in a patch size of 30 cm2, releasing 100 micrograms of estradiol per 24 hours.

Locations

Country Name City State
United Kingdom Ayr Hospital Ayr Scotland
United Kingdom Queen's Hospital Burton-upon-Trent England
United Kingdom Addenbrooke's Hospital Cambridge England
United Kingdom University Hospital of Wales Cardiff Wales
United Kingdom Velindre Cancer Center at Velindre Hospital Cardiff Wales
United Kingdom Walsgrave Hospital Coventry England
United Kingdom Mid Cheshire Hospitals Trust- Leighton Hopsital Crewe England
United Kingdom Mayday University Hospital Croydon England
United Kingdom Derbyshire Royal Infirmary Derby England
United Kingdom Castle Hill Hospital East Yorkshire England
United Kingdom Royal Devon and Exeter Hospital Exeter England
United Kingdom Beatson West of Scotland Cancer Centre Glasgow Scotland
United Kingdom Grantham and District Hospital Grantham, Lincolnshire England
United Kingdom Ipswich Hospital Ipswich England
United Kingdom Kidderminster Hospital Kidderminster Worcestershire England
United Kingdom Leeds Cancer Centre at St. James's University Hospital Leeds England
United Kingdom Charing Cross Hospital London England
United Kingdom St. Mary's Hospital London England
United Kingdom Maidstone Hospital Maidstone England
United Kingdom James Cook University Hospital Middlesbrough England
United Kingdom Nottingham City Hospital Nottingham England
United Kingdom Kings Mill Hospital Nottinghamshire England
United Kingdom George Eliot Hospital Nuneaton England
United Kingdom Alexandra Healthcare NHS Redditch, Worcestershire England
United Kingdom Hope Hospital Salford England
United Kingdom Scarborough General Hospital Scarborough England
United Kingdom Stepping Hill Hospital Stockport England
United Kingdom Hillingdon Hospital Uxbridge England
United Kingdom Walsall Manor Hospital Walsall England
United Kingdom Warwick Hospital Warwick England
United Kingdom Worthing Hospital Worthing England
United Kingdom Yeovil District Hospital Yeovil England

Sponsors (2)

Lead Sponsor Collaborator
University College, London Medical Research Council

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-Free Survival Up to 180 months
Primary Overall Survival Up to 180 months
Secondary Hormone activity by castrate levels of hormones Up to 180 months
Secondary Other toxicity Up to 180 months
Secondary Cardiovascular morbidity Up to 180 months
Secondary Cardiovascular mortality Up to 180 months
Secondary Quality of Life will be measured using patient-completed questionnaires, EORTC QLQ-C30 and PR25 which is prostate specific Up to 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A